Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

Table 5 Outcome in ITT and clinically evaluable patients

Parameter	Infusion	Bolus	P- value
Number of patients
ITT	120	120
Clinically evaluable	106	108
Meropenem-related length of mechanical ventilation
ITT	9 (5 to 13)	11 (6 to 17)	0.051
Clinically evaluable	9 (5 to 15)	12 (6 to 19)	0.058
Meropenem-related ICU LOS
ITT	10 (7 to 14)	12 (7 to 19)	0.044
Clinically evaluable	10 (7 to 16.5)	13 (8 to 21)	0.042
Meropenem-related hospital LOS
ITT	26 (17 to 38)	22 (12 to 35)	0.079
Clinically evaluable	28 (18 to 39)	25 (14 to 42)	0.412
ICU mortality
ITT	18 (15.0%)	25 (20.8%)	0.313
Clinically evaluable	14 (11.6%)	17 (14.2%)	0.701
Hospital mortality
ITT	21 (17.5%)	28 (23.3%)	0.337
Clinically evaluable	17 (16.0%)	19 (15.7%)	0.857
Duration of meropenem therapy (days)
ITT	7 (5 to 8)	8 (6 to 9)	0.041
Clinically evaluable	7 (6 to 8)	8 (7 to 10)	0.035
Total dose of meropenem (g)
ITT	24 (21 to 32)	48 (42 to 48)	< 0.0001
Clinically evaluable	24 (24 to 32)	48 (42 to 60)	< 0.0001

Values are presented as absolute (percentage) or median (interquartile range). ICU, intensive care unit; ITT, intention-to-treat; LOS, length of stay

ISSN: 1364-8535